.Regeneron is actually back along with long-lasting follow-up for its LAG-3 inhibitor and PD-1 preve...
.AstraZeneca has actually shared an early check out the efficiency of its in-house antibody-drug con...
.After revealing a stage 3 launch based on good midstage outcomes, iTeos as well as GSK are finally ...
.The FDA ought to be actually even more available as well as joint to discharge a surge in approvals...
.It's an extraordinarily hectic Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Therap...
.Atea Pharmaceuticals' antiviral has fallen short one more COVID-19 test, but the biotech still stor...
.Neurocrine Biosciences' schizophrenia plan pivot has failed. The biotech was unable to duplicate th...
.Sanofi has made a late entry to the radioligand party, spending one hundred thousand euros ($ 110 t...
.After F2G's first try to acquire a new lesson of antifungal to market was thwarted by the FDA, the ...
.Moderna has pledged to reduce R&D spending by $1.1 billion by 2027. The decision to shrink the s...